MagBio Genomics, Gaithersburg, Md, has launched the cfKapture 21 kit system, a circulating cell-free DNA (ccfDNA) isolation kit.

The kit includes a proprietary reagent that prevents postseparation degradation of plasma and ccfDNA fragments for up to 21 days at room temperature. The feature allows laboratories to transport and process samples safely without the need for extensive cold chain, making it possible to reduce costs, improve efficiency, and increase outreach for both local and international samples.

Compatible with any whole-blood collection tube, the kit is best used in combination with the MagBio Blood Stasis 21-ccfDNA tube to ensure recovery of the highest quality ccfDNA suitable for most liquid biopsy applications. Blood Stasis 21-ccfDNA is a direct draw whole-blood collection system with a proprietary blood stabilization reagent, compatible with almost all liquid biopsy applications for cancer genomic research and noninvasive prenatal testing. Other blood collection and stabilization systems contain potential formaldehyde-releasing compounds, which makes them unsuitable for many liquid biopsy applications.

“Currently, samples of plasma for the purposes of circulating cell-free DNA analysis (ccfDNA) need to be processed immediately,” says Hyacinth Ntchobo, PhD, CEO of MagBio Genomics. “However, to maintain the integrity of ccfDNA within the samples they have to be shipped frozen with dry ice for the duration of the transport cycle.”

Ntchobo adds, “Shipping on dry ice is not only expensive, but there is also a high risk of compromising ccfDNA integrity, especially for samples shipped overseas with long transit times. Because stabilizing plasma samples during transport remains a major hurdle in obtaining meaningful data from ccfDNA, MagBio developed the cfKapture 21 purification kit to overcome this challenge.”

The cfKapture 21 kit is for research use only.

For more information, visit MagBio Genomics.